Первичная и вторичная профилактика атеросклероза: как выбрать статин?

1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176–80.
2. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet 364 (9438): 937–52.
3. Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr Med Res Opin 2011; 27 (8): 1551–62.
4. Jones PH, Davidson MH, Stein EA et al. For the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152–60.
5. Nofer JR. Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study. Curr Opin Lipidol 2012; 23 (3): 260–2.
6. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. J Am Coll Cardiol 2007; 49: 2231–7.
7. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81 (5): 582–7.
8. La Rosa J et al. for Treating to New Targets (TNT) Investigators. NEJM 2005; 352, www.nejm.org.
9. A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292 (11): 1307–16.
10. Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Lancet 2010; 376 (9753): 1658–69.
11. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346 (7): 539–40.
12. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol 2009; 104 (11): 1603–5.
13. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. 
J Clin Invest 2003; 111: 1805–12.
14. McPherson RA, Matthew R. Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 22nd ed. Elsevier Saunders: Philadelphia 2011; p. 254–5.
15. Kappagoda CT, Amsterdam EA. Another look at the results of the JUPITER trial. Am J Cardiol 2009; 104 (11): 1603–5.
16. Hlatky MA. Expanding the Orbit of Primary Prevention – Moving beyond JUPITER. N Engl J Med 2008; 359: 2280–2.
17. O'Riordan M. FDA advisory panel votes in favor of broadened rosuvastatin indication 2009; http://www.theheart.org.
18. Sever PS, Dahlöf B, Poulter N, Wedel H et al. For the ASCOT Investigators. Lancet 2003; 361: 1149–58.
19. Colhoun HM, Betteridge DJ, Durrington PN et al. On behalf of the CARDS investigators*. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 2004; 364: 685–96.

Н.А.Ваулин

Городская клиническая больница №29 им. Н.Э.Баумана, Москва